96.62
price up icon1.91%   1.81
after-market 시간 외 거래: 96.62
loading

Blueprint Medicines Corp 주식(BPMC)의 최신 뉴스

pulisher
Nov 20, 2024

Blueprint Medicines (LTS:0HOJ) Enterprise Value : $5,746.9 Mil (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

Blueprint Medicines initiated with an Overweight at JPMorgan - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Victory Capital Management Inc. Trims Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 20, 2024
pulisher
Nov 18, 2024

JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Blueprint Medicines’ (BPMC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 18, 2024
pulisher
Nov 17, 2024

Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at Needham & Company LLC - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

HC Wainwright Reiterates Buy Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation - MSN

Nov 15, 2024
pulisher
Nov 14, 2024

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

Key Takeaways From Blueprint Medicines Analyst Ratings - Benzinga

Nov 14, 2024
pulisher
Nov 14, 2024

Blueprint Medicines (NASDAQ:BPMC) Now Covered by JPMorgan Chase & Co. - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Mastocytosis Treatment Market Forecasted for Major Expansion - openPR

Nov 14, 2024
pulisher
Nov 14, 2024

Entropy Technologies LP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 14, 2024
pulisher
Nov 09, 2024

Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Raised by US Bancorp DE - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

M&G Plc Makes New $9.10 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - MarketBeat

Nov 08, 2024
pulisher
Nov 05, 2024

Blueprint Medicines' SWOT analysis: stock soars on Ayvakit success, pipeline potential - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Blueprint Medicines discloses CDK2 inhibitors for cancer - BioWorld Online

Nov 05, 2024
pulisher
Nov 04, 2024

Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve

Nov 04, 2024
pulisher
Nov 04, 2024

Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Q1 Earnings Forecast for BPMC Issued By HC Wainwright - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Nov 03, 2024
pulisher
Nov 03, 2024

Blueprint Medicines (NASDAQ:BPMC) Given “Buy” Rating at Needham & Company LLC - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance

Nov 02, 2024
pulisher
Nov 01, 2024

Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales By Investing.com - Investing.com South Africa

Oct 31, 2024
pulisher
Oct 31, 2024

Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and Raised Guidance - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Blueprint Medicines Reports Strong Q3 2024 Results - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Blueprint Medicines Corp earnings beat by $0.07, revenue topped estimates - Investing.com Australia

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines shares buoyed by Ayvakit sales beat - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpHere's Why - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Needham & Company LLC Reaffirms "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines: Q3 Earnings Snapshot - Marketscreener.com

Oct 30, 2024
pulisher
Oct 30, 2024

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire

Oct 30, 2024
pulisher
Oct 28, 2024

When Can We Expect A Profit From Blueprint Medicines Corporation (NASDAQ:BPMC)? - Simply Wall St

Oct 28, 2024
pulisher
Oct 28, 2024

Assenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Oct 28, 2024
pulisher
Oct 27, 2024

Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic? - Yahoo Finance UK

Oct 27, 2024
pulisher
Oct 26, 2024

UBS Group Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC) - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart

Oct 25, 2024
pulisher
Oct 24, 2024

Analyst Ratings For Blueprint Medicines - Benzinga

Oct 24, 2024
pulisher
Oct 24, 2024

Blueprint Medicines (NASDAQ:BPMC) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

UBS sees Blueprint Medicines stock fairly valued, cites limited near-term catalysts - Investing.com UK

Oct 24, 2024
pulisher
Oct 23, 2024

Blueprint Medicines' SWOT analysis: stock outlook amid strong Ayvakit sales - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

Blueprint Medicines (BPMC) Scheduled to Post Earnings on Wednesday - MarketBeat

Oct 23, 2024
pulisher
Oct 22, 2024

SG Americas Securities LLC Has $233,000 Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Oct 21, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
자본화:     |  볼륨(24시간):